Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high31.00 13/04/17
52 week low17.25 26/09/16
52 week change 2.75 (11.11%)
4 week volume15,912,634 27/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Hardman Research: Development across portfolio

Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLC

Numis today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 4...

Interim Results for six months ended 31 Dec 2016

Announcement of half-year/second quarter financial results

Allergy Therapeutics recruits first patient in birch pollen trial

Allergy Therapeutics has recruited the first patient in its phase III study designed to evaluate the efficacy and safety of its u...

First Patient in Pivotal Phase III Birch Study

A statement giving an update on research (e.g. clinical trials)

Notice of Interim Results

Notification of the date financial results will be published

Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLC

Stifel today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and set its price target at 60p.

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
06/04/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’...
Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...

Latest discussion posts More

  • Malaria

    This AGY sponsored research from Bencard Adjuvant Systems (a division of Allergy Therapeutics UK) makes for interesting ...
    17-May-2017
    Totally Wired
  • Hardman note well worth reading, imo

    h p://hardmanandco.com/docs/default?]source/company?]docs/allergy?]therapeu cs?]documents/agy?]interim?]resultsupdate?] 5th?]april.pdf
    5-Apr-2017
    Baffler
  • Re: Interims TV Clips

    I nearly fell asleep the middle of this. Figures, stuff and more figures CL
    29-Mar-2017
    Chicken Lips

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.25%
BP19%
NATIONAL GRID18%
SIRIUS MINERALS18%
BARCLAYS16%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY